Table 1.
KEGG pathways analysis (P < .05) of 672 common potential targets with KOBAS tool
| Signalling pathway | Gene counts (n) | P‐value |
|---|---|---|
| Pathways in cancer | 35 | 1.91E−14 |
| Axon guidance | 20 | 1.36E−10 |
| PI3K‐Akt signalling pathway | 26 | 8.65E−10 |
| cGMP‐PKG signalling pathway | 17 | 1.47E−08 |
| Regulation of actin cytoskeleton | 19 | 1.76E−08 |
| Hippo signalling pathway | 16 | 3.00E−08 |
| Renin secretion | 11 | 4.61E−08 |
| HTLV‐I infection | 20 | 5.97E−08 |
| Focal adhesion | 17 | 2.01E−07 |
| Hedgehog signalling pathway | 9 | 3.46E−07 |
| Vascular smooth muscle contraction | 13 | 3.79E−07 |
| Wnt signalling pathway | 14 | 4.23E−07 |
| Ras signalling pathway | 17 | 9.12E−07 |
| MAPK signalling pathway | 18 | 9.21E−07 |
| Melanoma | 10 | 9.79E−07 |
| Proteoglycans in cancer | 16 | 1.09E−06 |
| FoxO signalling pathway | 13 | 1.20E−06 |
| Adherens junction | 10 | 1.38E−06 |
| Rap1 signalling pathway | 16 | 1.55E−06 |
| Colorectal cancer | 9 | 2.73E−06 |
| Metabolic pathways | 45 | 3.03E−06 |
| Adrenergic signalling in cardiomyocytes | 13 | 3.55E−06 |
| Calcium signalling pathway | 14 | 5.25E−06 |
| Gap junction | 10 | 5.67E−06 |
| cAMP signalling pathway | 14 | 1.52E−05 |
| Endocytosis | 16 | 1.84E−05 |
| Longevity regulating pathway—multiple species | 8 | 2.62E−05 |
| Insulin secretion | 9 | 2.78E−05 |
| Pancreatic cancer | 8 | 3.21E−05 |
| Cholinergic synapse | 10 | 3.64E−05 |
| Salivary secretion | 9 | 3.88E−05 |
| Dilated cardiomyopathy | 9 | 4.20E−05 |
| Signalling pathways regulating pluripotency of stem cells | 11 | 5.46E−05 |
| Longevity regulating pathway | 9 | 5.75E−05 |
| Phospholipase D signalling pathway | 11 | 6.15E−05 |
| Chronic myeloid leukaemia | 8 | 6.18E−05 |
| Pancreatic secretion | 9 | 6.68E−05 |
| Gastric acid secretion | 8 | 6.75E−05 |
| Phosphatidylinositol signalling system | 9 | 7.74E−05 |
| Oocyte meiosis | 10 | 8.13E−05 |
| Regulation of lipolysis in adipocytes | 7 | 8.39E−05 |
| Melanogenesis | 9 | 8.94E−05 |
| Chagas disease (American trypanosomiasis) | 9 | 1.18E−04 |
| Dopaminergic synapse | 10 | 1.25E−04 |
| ECM‐receptor interaction | 8 | 1.31E−04 |
| Oxytocin signalling pathway | 11 | 1.33E−04 |
| TGF‐beta signalling pathway | 8 | 1.53E−04 |
| Glioma | 7 | 1.96E−04 |
| GABAergic synapse | 8 | 2.05E−04 |
| Morphine addiction | 8 | 2.54E−04 |
| Notch signalling pathway | 6 | 2.70E−04 |
| Circadian entrainment | 8 | 3.32E−04 |
| Transcriptional misregulation in cancer | 11 | 3.84E−04 |
| Inflammatory mediator regulation of TRP channels | 8 | 4.04E−04 |
| Oestrogen signalling pathway | 8 | 4.30E−04 |
| Basal cell carcinoma | 6 | 5.27E−04 |
| Aldosterone synthesis and secretion | 7 | 6.74E−04 |
| MicroRNAs in cancer | 14 | 8.51E−04 |
| Serotonergic synapse | 8 | 9.19E−04 |
| Small cell lung cancer | 7 | 9.36E−04 |
| Glutamatergic synapse | 8 | 1.02E−03 |
| Viral carcinogenesis | 11 | 1.06E−03 |
| Purine metabolism | 10 | 1.18E−03 |
| Thyroid hormone signalling pathway | 8 | 1.26E−03 |
| GnRH signalling pathway | 7 | 1.27E−03 |
| Neurotrophin signalling pathway | 8 | 1.39E−03 |
| Platelet activation | 8 | 1.54E−03 |
| AMPK signalling pathway | 8 | 1.78E−03 |
| Thyroid hormone synthesis | 6 | 1.80E−03 |
| Endocrine resistance | 7 | 1.80E−03 |
| Type II diabetes mellitus | 5 | 1.86E−03 |
| Progesterone‐mediated oocyte maturation | 7 | 1.90E−03 |
| Amoebiasis | 7 | 2.11E−03 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 6 | 2.19E−03 |
| AGE‐RAGE signalling pathway in diabetic complications | 7 | 2.23E−03 |
| Choline metabolism in cancer | 7 | 2.23E−03 |
| Cytokine‐cytokine receptor interaction | 12 | 2.53E−03 |
| Mucin type O‐Glycan biosynthesis | 4 | 2.63E−03 |
| Glycosphingolipid biosynthesis—ganglio series | 3 | 3.10E−03 |
| Hypertrophic cardiomyopathy (HCM) | 6 | 3.73E−03 |
| Prostate cancer | 6 | 5.14E−03 |
| Lysosome | 7 | 6.19E−03 |
| Glycosaminoglycan biosynthesis—chondroitin sulphate/ dermatan sulphate | 3 | 6.32E−03 |
| Long‐term potentiation | 5 | 6.60E−03 |
| Amphetamine addiction | 5 | 7.00E−03 |
| Central carbon metabolism in cancer | 5 | 7.00E−03 |
| Renal cell carcinoma | 5 | 7.00E−03 |
| Inositol phosphate metabolism | 5 | 8.76E−03 |
| Retrograde endocannabinoid signalling | 6 | 9.06E−03 |
| Ubiquitin mediated proteolysis | 7 | 1.06E−02 |
| Tight junction | 7 | 1.14E−02 |
| Ovarian steroidogenesis | 4 | 1.24E−02 |
| Complement and coagulation cascades | 5 | 1.32E−02 |
| Dorso‐ventral axis formation | 3 | 1.45E−02 |
| Thyroid cancer | 3 | 1.59E−02 |
| Pentose phosphate pathway | 3 | 1.59E−02 |
| Toxoplasmosis | 6 | 1.84E−02 |
| beta‐Alanine metabolism | 3 | 1.87E−02 |
| Circadian rhythm | 3 | 1.87E−02 |
| Acute myeloid leukaemia | 4 | 1.87E−02 |